Natera, Inc. (NTRA)
USD 146.95
(2.56%)
USD 146.95
(2.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -383.27 Million USD | 24.66% |
| 2022 | -520.8 Million USD | -16.14% |
| 2021 | -451.53 Million USD | -121.73% |
| 2020 | -205.95 Million USD | -64.96% |
| 2019 | -104.4 Million USD | -7.81% |
| 2018 | -107.12 Million USD | 10.85% |
| 2017 | -125.81 Million USD | -38.44% |
| 2016 | -93.37 Million USD | -42.41% |
| 2015 | -61.23 Million USD | -1684.1% |
| 2014 | 4.21 Million USD | 118.62% |
| 2013 | -22.74 Million USD | -22.44% |
| 2012 | -18.49 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -63.65 Million USD | 16.93% |
| 2024 Q2 | -35.98 Million USD | 52.18% |
| 2023 Q2 | -107.9 Million USD | 19.3% |
| 2023 Q1 | -133.71 Million USD | 1.29% |
| 2023 FY | - USD | 24.66% |
| 2023 Q4 | -74.11 Million USD | 29.8% |
| 2023 Q3 | -105.57 Million USD | 2.16% |
| 2022 Q2 | -138.32 Million USD | -3.86% |
| 2022 Q3 | -113.82 Million USD | 17.71% |
| 2022 Q4 | -135.47 Million USD | -19.02% |
| 2022 FY | - USD | -16.14% |
| 2022 Q1 | -133.18 Million USD | 1.72% |
| 2021 Q2 | -113.7 Million USD | -84.45% |
| 2021 Q4 | -135.52 Million USD | 9.0% |
| 2021 FY | - USD | -121.73% |
| 2021 Q3 | -148.92 Million USD | -30.97% |
| 2021 Q1 | -61.64 Million USD | 11.52% |
| 2020 Q3 | -54.02 Million USD | -8.63% |
| 2020 Q4 | -69.66 Million USD | -28.95% |
| 2020 FY | - USD | -64.96% |
| 2020 Q1 | -32.88 Million USD | -0.81% |
| 2020 Q2 | -49.73 Million USD | -51.24% |
| 2019 Q3 | -34.8 Million USD | -25.21% |
| 2019 FY | - USD | -7.81% |
| 2019 Q4 | -32.62 Million USD | 6.29% |
| 2019 Q1 | -31.29 Million USD | -15.12% |
| 2019 Q2 | -27.8 Million USD | 11.16% |
| 2018 Q1 | -30.38 Million USD | 26.2% |
| 2018 Q3 | -24.82 Million USD | 20.32% |
| 2018 Q4 | -27.18 Million USD | -9.51% |
| 2018 FY | - USD | 10.85% |
| 2018 Q2 | -31.15 Million USD | -2.54% |
| 2017 Q1 | -33.97 Million USD | 4.89% |
| 2017 Q4 | -41.16 Million USD | -73.1% |
| 2017 FY | - USD | -38.44% |
| 2017 Q3 | -23.78 Million USD | 13.37% |
| 2017 Q2 | -27.45 Million USD | 19.2% |
| 2016 Q1 | -8.57 Million USD | 61.02% |
| 2016 FY | - USD | -42.41% |
| 2016 Q4 | -35.71 Million USD | -38.62% |
| 2016 Q3 | -25.76 Million USD | -11.87% |
| 2016 Q2 | -23.03 Million USD | -168.77% |
| 2015 Q1 | -5.55 Million USD | -238.69% |
| 2015 Q3 | -16.45 Million USD | 9.38% |
| 2015 FY | - USD | -1684.1% |
| 2015 Q4 | -21.98 Million USD | -33.63% |
| 2015 Q2 | -18.15 Million USD | -226.96% |
| 2014 Q2 | 1.66 Million USD | 123.96% |
| 2014 Q3 | 6.28 Million USD | 278.57% |
| 2014 Q4 | 4 Million USD | -36.32% |
| 2014 FY | - USD | 118.62% |
| 2014 Q1 | -6.93 Million USD | -154.01% |
| 2013 Q4 | -2.72 Million USD | 29.17% |
| 2013 Q1 | -9.43 Million USD | 0.0% |
| 2013 FY | - USD | -22.44% |
| 2013 Q3 | -3.85 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -117.56 Million USD | -226.012% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -3896.188% |
| Aspira Women's Health Inc. | -16.49 Million USD | -2224.153% |
| Biodesix, Inc. | -37.1 Million USD | -933.005% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -15322.582% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -4923.734% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -4923.734% |
| Bionano Genomics, Inc. | -213.6 Million USD | -79.433% |
| CareDx, Inc | -89.65 Million USD | -327.491% |
| Check-Cap Ltd. | -17.64 Million USD | -2071.658% |
| Castle Biosciences, Inc. | -45.02 Million USD | -751.27% |
| DarioHealth Corp. | -53.49 Million USD | -616.484% |
| Exact Sciences Corporation | 41.87 Million USD | 1015.264% |
| Fulgent Genetics, Inc. | -46.55 Million USD | -723.329% |
| Guardant Health, Inc. | -433.3 Million USD | 11.546% |
| ICON Public Limited Company | 1.63 Billion USD | 123.49% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 131.476% |
| Illumina, Inc. | -608 Million USD | 36.961% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -4250.116% |
| iSpecimen Inc. | -9.1 Million USD | -4110.103% |
| Standard BioTools Inc. | -54.45 Million USD | -603.814% |
| MDxHealth SA | -30.46 Million USD | -1157.962% |
| 23andMe Holding Co. | -291.87 Million USD | -31.316% |
| Medpace Holdings, Inc. | 363.15 Million USD | 205.541% |
| Myriad Genetics, Inc. | -67.8 Million USD | -465.304% |
| Mainz Biomed B.V. | -25.01 Million USD | -1432.417% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -3817.053% |
| NeoGenomics, Inc. | -17.6 Million USD | -2076.839% |
| Neogen Corporation | 182.59 Million USD | 309.903% |
| Inotiv, Inc. | -26.5 Million USD | -1345.997% |
| OpGen, Inc. | -29.51 Million USD | -1198.756% |
| OPKO Health, Inc. | -65.51 Million USD | -485.011% |
| Psychemedics Corporation | -251 Thousand USD | -152599.602% |
| Prenetics Global Limited | -47.89 Million USD | -700.224% |
| Prenetics Global Limited | -47.89 Million USD | -700.224% |
| Precipio, Inc. | -4.31 Million USD | -8776.239% |
| Personalis, Inc. | -96.8 Million USD | -295.918% |
| RadNet, Inc. | 292.78 Million USD | 230.907% |
| Sera Prognostics, Inc. | -35.28 Million USD | -986.168% |
| Sotera Health Company | 514.14 Million USD | 174.547% |
| Neuronetics, Inc. | -22.75 Million USD | -1584.063% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -22619.384% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -22619.384% |
| Trinity Biotech plc | -24.09 Million USD | -1490.489% |
| T2 Biosystems, Inc. | -43.87 Million USD | -773.564% |
| Twist Bioscience Corporation | -176.7 Million USD | -116.902% |
| Exagen Inc. | -19.15 Million USD | -1901.128% |